Sinopharm Revises Plan to Reform its State-Owned Enterprise Structure

Sinopharm, China's largest state-owned pharma, has submitted a plan to China's Assets Supervision and Administration Commission that would strengthen the power of its Board of Directors. Two years ago, Sinopharm was chosen as a pilot program for reform of China's state-owned enterprises as a way to make the SOEs more competitive, a mixed-ownership plan. A more powerful Board would implement market-based strategies for Sinopharm, reducing the power of the government to make decisions for China's largest pharma. Sinopharm is formally known as China National Pharmaceutical Group. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.